Comprehensive Report on the Radiopharmaceutical Candidate:Tc-G3-(G3S)3C

Preamble: Approach to this Report

This document outlines the comprehensive information typically compiled for a novel radiopharmaceutical agent. Due to the absence of specific research data pertaining to "Tc-G3-(G3S)3C" within the provided reference materials, this report will serve as an illustrative template. It will detail the requisite sections and the nature of the scientific and clinical information necessary for a complete monograph of such an agent. Where specific data forTc-G3-(G3S)3C is unavailable, examples derived from the provided information on other pharmaceutical compounds and development programs will be used to demonstrate the type of content, depth of analysis, and critical considerations expected in a thorough evaluation of a novel radiopharmaceutical.

1. Nomenclature and Overview ofTc-G3-(G3S)3C

The precise identification and basic characterization of a new pharmaceutical entity are foundational for all subsequent scientific and regulatory discussions. This section would establish the unambiguous identity ofTc-G3-(G3S)3C.

1.1. Chemical Name and Structure

A comprehensive report would commence with the formal chemical name ofTc-G3-(G3S)3C, adhering to nomenclature standards set by the International Union of Pure and Applied Chemistry (IUPAC) or other relevant chemical abstracting services. This ensures universal understanding and precise identification. Accompanying the chemical name, a detailed structural representation, likely a 2D chemical structure diagram and potentially a 3D conformational model, would be provided. This visual depiction would clearly illustrate the G3-(G3S)3C ligand, the chelating moiety responsible for binding the technetium-99m radionuclide, and the coordination chemistry of the resulting technetium complex. Such structural information is vital for understanding its physicochemical properties and potential interactions at a molecular level. For example, fundamental identifiers like CAS registry numbers and molecular formulas are standard for compounds such as PL-3994 [1] and Esaxerenone.[3] The CAS registry number, in particular, serves as a unique, universal identifier, critical for database searches and cross-referencing scientific literature.

1.2. Synonyms and Code Names

Throughout its research and development lifecycle, a drug candidate often accumulates various identifiers. This subsection would list any known synonyms, laboratory codes (e.g., assigned by the originating institution or company), or investigational drug codes used forTc-G3-(G3S)3C. For instance, the investigational agent QLM2011 is primarily identified by this code, though the provided information notes a lack of synonyms.[5] Conversely, FAB 117-HC is also known by synonyms such as "FAB 117," "FIB 117," and "NeuroSave" [6], and Zipalertinib is recognized as CLN-081 and TAS6417.[7] A comprehensive compilation of these alternative names is crucial for conducting thorough literature reviews and for understanding the drug's development history as presented across diverse publications, patents, and regulatory documents. Missing a code name could mean overlooking significant data.

1.3. Drug Class (Radiopharmaceutical)

Tc-G3-(G3S)3C is, by its nomenclature, classified as a radiopharmaceutical. This primary classification immediately signals a range of specific considerations, including radionuclide properties, radiation safety, dosimetry, and specialized handling and administration protocols. Further sub-classification would be based on its intended mechanism and use. If the G3-(G3S)3C ligand targets a specific biological molecule or pathway, the agent might be further classified as a targeted radiopharmaceutical. Its intended application (e.g., diagnostic imaging agent or targeted radioligand therapy) would also refine its classification. For comparison, Tenecteplase is classified as a plasminogen activator and a thrombolytic agent [9], while Pazufloxacin is a fluoroquinolone antibiotic [11], and Opicapone is a catechol-O-methyltransferase (COMT) inhibitor.[13] Each classification provides an immediate framework for understanding the general properties, expected mechanism of action, and therapeutic or diagnostic context of the agent.

1.4. Brief Introduction toTc-G3-(G3S)3C and its Intended Use

This section would offer a concise introductory overview ofTc-G3-(G3S)3C, summarizing its nature, potential novelty, and the primary medical or scientific question it aims to address. It would clearly state whether the agent is being developed for diagnostic purposes (e.g., imaging a particular disease state or physiological process) or for therapeutic applications (which is less common for 99mTc-based agents alone but could be relevant if the ligand itself has therapeutic properties or if it's a precursor to a therapeutically-labeled version). The specific disease, condition, or biological target would be identified. For example, Tesamorelin is introduced as a growth hormone-releasing factor (GHRF) analog developed for the treatment of HIV-associated lipodystrophy [15], and Zipalertinib is an EGFR tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC) harboring specific EGFR mutations.[17] The introduction forTc-G3-(G3S)3C would similarly frame its purpose based on the characteristics of the G3-(G3S)3C ligand and its interaction with biological systems. This initial summary is vital for orienting the reader to the fundamental purpose and context of the drug before delving into more detailed scientific data.

2. Scientific Profile

A thorough understanding of a radiopharmaceutical's scientific profile, encompassing its physicochemical properties, the characteristics of its radionuclide component, its formulation, and its mechanism of action, is essential for its development, application, and regulatory evaluation.

2.1. Physicochemical Properties

This subsection would provide detailed information regarding the physicochemical characteristics of both the G3-(G3S)3C ligand and the finalTc-G3-(G3S)3C complex. Key parameters include:

• Molecular Weight: For the ligand and the complex.
• Appearance: Physical state (e.g., solid, liquid) and color.
• Solubility: In aqueous solutions (e.g., saline, buffers at physiological pH) and relevant organic solvents. This impacts formulation and in vivo behavior.
• Lipophilicity: Often expressed as the partition coefficient (LogP or LogD), which influences membrane permeability, biodistribution, and non-specific binding.
• pKa: Acid dissociation constant(s), relevant for understanding ionization state at physiological pH and thus solubility and binding characteristics.
• Stability: Chemical stability of the ligand and the radiolabeled complex under various conditions, such as temperature, pH, and exposure to light or oxidizing/reducing agents. Shelf-life data would be included.
• Radiochemical Purity and Impurities: Methods for determining radiochemical purity (e.g., HPLC, TLC) and specifications for acceptable levels. Identification and quantification of any significant radiochemical or chemical impurities.
• Stability of the 99mTc-label: Critical for ensuring that the radionuclide remains attached to the targeting ligand in vivo, preventing undesired accumulation of free 99mTc (e.g., as pertechnetate).

For instance, information on Pazufloxacin includes its melting point, boiling point, density, and solubility [19], while Tenecteplase's molecular formula and CAS number are provided.[20] These properties are fundamental as they dictate aspects from drug formulation and route of administration to in vivo absorption, distribution, and the overall stability of the pharmaceutical product. For radiopharmaceuticals likeTc-G3-(G3S)3C, the stability of the radionuclide-ligand bond is a particularly critical quality attribute, ensuring that the radioactivity is delivered to and remains at the intended target.

2.2. Radionuclide Characteristics (Technetium-99m)

The choice of radionuclide is central to the function and utility of any radiopharmaceutical.Tc-G3-(G3S)3C utilizes Technetium-99m (99mTc), one of the most widely used radionuclides in diagnostic nuclear medicine. Its key characteristics relevant to this agent include:

• Physical Half-Life: T1/2​=6.01 hours. This relatively short half-life is long enough to allow for preparation, administration, and imaging, yet short enough to minimize the radiation dose to the patient.
• Type and Energy of Emissions: 99mTc decays by isomeric transition, emitting a monoenergetic gamma photon with an energy of 140 keV. This energy is ideal for imaging with standard gamma cameras (SPECT systems), offering good tissue penetration and efficient detection.
• Absence of Particulate Emissions: The lack of alpha or beta particles minimizes the radiation dose to tissues, making it suitable for diagnostic applications.
• Source: 99mTc is readily available in clinical settings from 99Mo/99mTc generators, where the parent radionuclide Molybdenum-99 (99Mo, T1/2​=66 hours) decays to 99mTc. This on-site availability is a significant logistical advantage.
• Chemistry: Technetium possesses a versatile coordination chemistry, allowing it to be complexed with a wide variety of chelating agents attached to targeting biomolecules.

These favorable characteristics – ideal gamma energy, appropriate half-life, and convenient availability – explain the widespread use of 99mTc in diagnostic imaging and are integral to the potential utility ofTc-G3-(G3S)3C as an imaging agent.

2.3. Formulation and Presentation

This section would describe the pharmaceutical formulation ofTc-G3-(G3S)3C as it is intended for clinical use. Key aspects include:

• Product Form: Whether the G3-(G3S)3C ligand is supplied as a sterile, lyophilized kit for on-site radiolabeling with 99mTc (common for many 99mTc agents), or as a ready-to-use solution (less common for short-lived radionuclides like 99mTc).
• Excipients: A list of all non-active ingredients in the formulation (e.g., buffering agents, stabilizers, bulking agents for lyophilization, antioxidants like gentisic acid or ascorbic acid often used in 99mTc kits). The rationale for their inclusion would be discussed.
• Reconstitution and Radiolabeling: If supplied as a kit, detailed instructions for reconstitution with sterile saline and subsequent labeling with sodium pertechnetate (99mTcO4−​) eluted from a generator. This would include incubation times, temperatures, and any specific conditions required for optimal labeling yield and purity.
• Quality Control: Recommended quality control procedures for the final radiolabeled product, such as determination of radiochemical purity (e.g., percentage of 99mTc bound to G3-(G3S)3C versus free pertechnetate or other radiochemical impurities).
• Storage Conditions: Recommended storage conditions (e.g., temperature, light protection) and shelf-life for both the unlabelled kit and the final radiolabeledTc-G3-(G3S)3C preparation. The usable period post-radiolabeling is particularly important due to radionuclide decay and potential degradation of the complex.
• Appearance of Final Product: Description of the final radiolabeled solution (e.g., clear, colorless).

Examples from other drug classes illustrate the importance of such details. Egrifta WR (Tesamorelin), a peptide, is supplied as a lyophilized powder requiring specific reconstitution and storage protocols.[21] Similarly, Tenecteplase (TNKase) is a lyophilized powder with specific reconstitution instructions and known incompatibilities (e.g., with dextrose-containing solutions).[23] ForTc-G3-(G3S)3C, these formulation and presentation details are critical for ensuring consistent product quality, proper preparation by nuclear pharmacy or clinical staff, safe administration, and ultimately, reliable diagnostic or therapeutic outcomes.

2.4. Mechanism of Action (MoA)

The mechanism of action describes howTc-G3-(G3S)3C exerts its effects at a molecular, cellular, and physiological level. This is fundamentally determined by the biological properties of the G3-(G3S)3C ligand component, as 99mTc primarily serves as a detectable tracer (for diagnostics) or a source of localized radiation (less common for 99mTc in therapeutics). This section would detail:

• Biological Target: Identification of the specific biological molecule (e.g., receptor, enzyme, transporter, antigen) or physiological process that the G3-(G3S)3C ligand is designed to interact with. The affinity and specificity of this interaction are key.
• Molecular Interaction: How G3-(G3S)3C binds to its target.
• Consequences of Interaction:
• For a Diagnostic Agent: How the biodistribution, accumulation, and retention ofTc-G3-(G3S)3C at the target site (due to ligand-target interaction) allow for visualization and quantification of the target's expression or activity. The uptake mechanism (e.g., receptor-mediated endocytosis, passive diffusion followed by trapping, enzyme substrate conversion) would be described. The signal generated by 99mTc would then reflect the density or activity of this target.
• For a Therapeutic Agent (if applicable): If the G3-(G3S)3C ligand itself possesses therapeutic activity, or if the 99mTc (though primarily a gamma emitter, Auger electrons could have very localized effects if concentrated intranuclearly) contributes to a therapeutic effect, this would be explained. More commonly, a ligand developed for 99mTc imaging might later be labeled with a therapeutic radionuclide; this potential would be noted.

Illustrative examples of MoA descriptions for other drug classes include Zipalertinib, an EGFR TKI that specifically targets EGFR exon 20 insertion mutations in NSCLC [24], and JNJ-61610588 (Onvatilimab), a monoclonal antibody targeting the immune checkpoint protein VISTA.[26] Pazufloxacin, an antibiotic, functions by inhibiting bacterial DNA gyrase and topoisomerase IV.[28] The MoA forTc-G3-(G3S)3C would be specific to the biological role and interactions of the G3-(G3S)3C peptide/protein component. Understanding the MoA is crucial for interpreting imaging results (if diagnostic), predicting efficacy, anticipating potential side effects related to on-target or off-target interactions, and guiding patient selection.

Table 1: Illustrative Physicochemical and Radiochemical Properties of a Novel 99mTc-Radiopharmaceutical (e.g.,Tc-G3-(G3S)3C)

Property	Description
Ligand (G3-(G3S)3C)
Molecular Weight (Da)	Value specific to G3-(G3S)3C
Appearance	e.g., White lyophilized powder
Solubility	e.g., Soluble in water, saline; specific concentrations
LogP / LogD	Value indicating lipophilicity/hydrophilicity
Stability (Kit)	e.g., Stable for X months at Y°C when protected from light
Radionuclide (99mTc)
Physical Half-life	6.01 hours
Principal Photon Energy	140 keV (gamma)
Mode of Production	99Mo/99mTc generator
Radiolabeled Complex (Tc-G3-(G3S)3C)
Molecular Weight (Da)	Calculated for the complex
Radiochemical Purity (RCP)	e.g., ≥95% as determined by HPLC/TLC
Stability (Post-Labeling)	e.g., Stable for Y hours at room temperature, RCP remains >90%
Appearance of Solution	e.g., Clear, colorless solution

This table provides a template. Actual values forTc-G3-(G3S)3C would require specific experimental determination.

3. Pharmacological Profile

The pharmacological profile ofTc-G3-(G3S)3C encompasses its pharmacodynamic (PD) effects – what the drug does to the body – and its pharmacokinetic (PK) characteristics – what the body does to the drug. For a radiopharmaceutical, PK is often referred to as biokinetics, which forms the basis for radiation dosimetry.

3.1. Pharmacodynamics (PD)

Pharmacodynamic studies aim to confirm thatTc-G3-(G3S)3C interacts with its intended biological target and elicits the expected physiological or biochemical response. This involves:

• Target Engagement: Evidence from in vitro (e.g., cell binding assays, receptor affinity studies using radioligand binding assays) and in vivo studies (e.g., competitive displacement studies, imaging in animal models with known target expression) demonstrating specific binding of the G3-(G3S)3C ligand component to its target. The affinity (Kd​ or IC50​) and specificity (selectivity over other potential binding sites) would be quantified.
• Dose-Response Relationships: If applicable (more so for therapeutic effects or for optimizing imaging signal), studies defining the relationship between the administered dose (activity for radiopharmaceuticals) and the magnitude of the observed effect (e.g., target saturation, imaging contrast, or a physiological change).
• Mechanism of Uptake/Retention (for diagnostics): Elucidation of how the agent accumulates in target tissues. For example, ifTc-G3-(G3S)3C targets a receptor, pharmacodynamic studies might investigate receptor density effects on uptake, internalization rates, and retention times.
• Biological Effects (if any beyond imaging): While 99mTc is primarily a gamma emitter for imaging, the G3-(G3S)3C ligand itself might have some intrinsic pharmacological activity. Any such effects would be characterized.

For comparison, the pharmacodynamic effects of Tesamorelin include increased levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).[30] Opicapone's pharmacodynamics involve the inhibition of COMT activity and the subsequent impact on levodopa pharmacokinetics.[33] For AZD5492, pharmacodynamic assessments would involve relevant biomarkers for Systemic Lupus Erythematosus (SLE) and Idiopathic Inflammatory Myopathies (IIM).[36] ForTc-G3-(G3S)3C, PD studies would be crucial to validate its targeting mechanism and ensure that its localization accurately reflects the biological process or target it is designed to assess.

3.2. Pharmacokinetics (PK) / Biokinetics

The pharmacokinetic profile of a radiopharmaceutical details its absorption, distribution, metabolism, and excretion (ADME), collectively termed biokinetics. This information is vital for determining optimal imaging or treatment protocols and is fundamental for calculating patient-specific radiation absorbed doses.

3.2.1. Absorption and Distribution (Biodistribution)

Since most radiopharmaceuticals, including likelyTc-G3-(G3S)3C, are administered intravenously, "absorption" into the systemic circulation is immediate and complete. The primary focus is therefore on distribution:

• Blood Clearance: The rate at whichTc-G3-(G3S)3C is cleared from the bloodstream. This is often characterized by a multi-exponential decay, with initial rapid distribution phases followed by slower elimination phases. Parameters such as clearance rate (CL) and half-lives (t1/2α​, t1/2β​) would be reported.
• Protein Binding: The extent to whichTc-G3-(G3S)3C binds to plasma proteins (e.g., albumin, globulins). High protein binding can affect tissue distribution and clearance.
• Tissue Uptake and Retention: Quantitative data on the uptake of the radiopharmaceutical in target tissues/organs versus non-target organs over time. This is typically determined through serial imaging studies (e.g., SPECT in animal models and humans) and/or tissue sampling in preclinical models. The time to peak uptake (Tmax​) and the duration of retention in the target tissue are important parameters.
• Volume of Distribution (Vd​): An apparent volume indicating the extent of distribution into body tissues.
• Critical Organs: Identification of organs that receive the highest concentration or longest exposure to the radiopharmaceutical, as these are critical for radiation dosimetry calculations.

For example, Esaxerenone's pharmacokinetic profile, including its absorption, distribution characteristics (such as blood-to-plasma ratio), is discussed in [38] and.[38] The penetration of Pazufloxacin into suction blister fluid provides an example of tissue distribution assessment.[37] ForTc-G3-(G3S)3C, comprehensive biodistribution studies in appropriate animal models followed by human studies would be essential to map its journey through the body, identify target accumulation, and quantify uptake in non-target organs.

3.2.2. Metabolism

This section addresses the metabolic fate of theTc-G3-(G3S)3C complex:

• In Vivo Stability: Assessment of whether the 99mTc remains stably complexed to the G3-(G3S)3C ligand under physiological conditions. Dissociation of the radionuclide from the ligand would lead to altered biodistribution (e.g., uptake of free pertechnetate in thyroid, salivary glands, stomach) and compromise the intended targeting.
• Ligand Metabolism: Whether the G3-(G3S)3C ligand itself undergoes metabolic transformation (e.g., enzymatic cleavage if it's a peptide).
• Identification of Metabolites: Characterization of any significant radiometabolites or metabolites of the ligand, and assessment of their biodistribution, activity, and potential toxicity.
• Enzymes Involved: Identification of any specific enzyme systems (e.g., peptidases, cytochrome P450 enzymes) responsible for metabolism.

The metabolic stability of the radiopharmaceutical is crucial for it to reach and interact with its target effectively. Esaxerenone, for instance, undergoes metabolism via CYP3A, UGTs, and hydrolysis, leading to several metabolites.[38] Tesamorelin, a peptide, is metabolized via proteolysis.[39] ForTc-G3-(G3S)3C, ensuring the stability of the 99mTc-G3-(G3S)3C bond is paramount. Any breakdown products could lead to misinterpretation of diagnostic images or unintended radiation exposure to non-target tissues.

3.2.3. Excretion Pathways

Understanding the routes and rates of elimination ofTc-G3-(G3S)3C from the body is critical for several reasons, including determining the biological half-life of the agent and calculating radiation doses to excretory organs (e.g., kidneys, bladder, liver, intestines).

• Primary Routes: Identification of the major pathways of excretion, typically renal (urine) and/or hepatobiliary (feces).
• Excretion Rate: The speed at which the radiopharmaceutical and its metabolites are eliminated. This is often expressed as a percentage of the administered dose excreted over specific time intervals.
• Urinary and Fecal Excretion: Quantification of the cumulative percentage of radioactivity excreted in urine and feces over time.
• Biological Half-Life (T1/2b​): The time taken for the body to eliminate half of the administered radiopharmaceutical through biological processes (metabolism and excretion).
• Effective Half-Life (T1/2eff​): The combined effect of physical decay of 99mTc and biological clearance, calculated as (T1/2p​×T1/2b​)/(T1/2p​+T1/2b​), where T1/2p​ is the physical half-life.

Esaxerenone is excreted via both urine (38.5% of radioactivity) and feces (54.0%).[38] Pazufloxacin's renal excretion and the potential involvement of transporters like P-glycoprotein have been studied.[40] ForTc-G3-(G3S)3C, identifying these pathways would be crucial for predicting its clearance from non-target tissues and for dosimetry, especially for organs like the kidneys and bladder if renal excretion is significant.

3.2.4. Radiation Dosimetry

Radiation dosimetry is a unique and essential component of the pharmacological profile for any radiopharmaceutical. It involves calculating the absorbed radiation dose delivered to various organs and tissues, as well as the total body effective dose, following administration ofTc-G3-(G3S)3C.

• Methodology: Typically, dosimetry calculations are performed using standardized methodologies such as the Medical Internal Radiation Dose (MIRD) schema, often implemented with software like OLINDA/EXM (Organ Level INternal Dose Assessment/EXponential Modeling).
• Biokinetic Data Input: These calculations rely heavily on the quantitative biokinetic data obtained from human studies (or extrapolated from animal studies for initial estimates), including serial measurements of radioactivity in source organs (organs with significant uptake) and remainder of the body over time. Residence times (cumulated activity) in each source organ are calculated.
• Absorbed Dose Estimates: Results are expressed as absorbed dose per unit of administered activity (e.g., mGy/MBq or rad/mCi) for critical organs (e.g., target tissue, bone marrow, gonads, liver, kidneys, spleen, bladder wall) and the whole body.
• Effective Dose: An estimate of the overall radiation risk to the patient, taking into account the differing radiosensitivities of various organs.

This information is paramount for assessing the radiation risk to the patient, ensuring that the diagnostic or therapeutic benefit outweighs this risk, and adhering to the principles of radiation protection (As Low As Reasonably Achievable - ALARA). While no direct dosimetry data forTc-G3-(G3S)3C is available in the provided materials, this section is a non-negotiable component of its full report and would be populated with data from dedicated human biokinetic and dosimetry studies.

Table 2: Illustrative Summary of Key Pharmacokinetic Parameters and Radiation Dosimetry Estimates for a Novel 99mTc-Radiopharmaceutical (e.g.,Tc-G3-(G3S)3C)

Parameter	Value / Description
Pharmacokinetics / Biokinetics
Blood Clearance (t1/2, fast phase)	e.g., X minutes
Blood Clearance (t1/2, slow phase)	e.g., Y hours
Volume of Distribution (Vd​)	e.g., Z L/kg
Plasma Protein Binding	e.g., X%
Major Excretion Route(s)	e.g., Renal (X% in 24h urine), Hepatobiliary (Y% in 48h feces)
Effective Half-life (T1/2eff​) in Body	e.g., W hours
Radiation Dosimetry (Estimated Absorbed Doses per MBq Administered)
Target Organ/Tissue	e.g., A mGy/MBq
Liver	e.g., B mGy/MBq
Kidneys	e.g., C mGy/MBq
Spleen	e.g., D mGy/MBq
Red Marrow	e.g., E mGy/MBq
Bladder Wall (2-hr void)	e.g., F mGy/MBq
Gonads (Ovaries/Testes)	e.g., G mGy/MBq / H mGy/MBq
Total Body	e.g., I mGy/MBq
Effective Dose (mSv/MBq)	e.g., J mSv/MBq (ICRP Publication 103 weighting factors)

This table provides a template. Actual values forTc-G3-(G3S)3C would be derived from specific preclinical and human clinical studies.

4. Development Program

The development program for a new radiopharmaceutical likeTc-G3-(G3S)3C involves a structured progression from non-clinical research to human clinical trials, designed to establish its safety and efficacy for the intended indication.

4.1. Non-Clinical Studies

Preclinical research forms the bedrock of drug development, providing essential proof-of-concept, safety, and pharmacokinetic data before human administration. ForTc-G3-(G3S)3C, this phase would typically include:

• In Vitro Studies:
• Binding assays to confirm affinity and specificity of the G3-(G3S)3C ligand for its biological target using cell lines or tissue preparations.
• Cellular uptake, internalization, and efflux studies.
• Stability studies of the ligand and the radiolabeled complex in biological matrices (e.g., plasma, serum).
• In Vivo Animal Studies:
• Biodistribution Studies: Administration ofTc-G3-(G3S)3C to appropriate animal models (e.g., rodents, non-human primates) followed by serial imaging (SPECT) and/or ex vivo organ counting to determine the time-course of uptake and clearance in target and non-target organs. These data are crucial for initial radiation dosimetry estimates.
• Efficacy/Proof-of-Concept Studies: In animal models of the target disease, demonstration thatTc-G3-(G3S)3C can effectively image the disease process (for diagnostics) or elicit a therapeutic response (if applicable). For example, if targeting tumors, studies in xenograft or syngeneic tumor models would assess tumor uptake and contrast.
• Pharmacokinetic Studies: Characterization of ADME parameters in animals.
• Safety Pharmacology: Studies to evaluate potential effects on major physiological systems (cardiovascular, respiratory, central nervous system) at doses exceeding the anticipated clinical dose.
• Toxicology Studies: Acute, sub-chronic, and potentially chronic toxicity studies (depending on intended use and dosing regimen) to identify potential adverse effects and establish a safety margin. For radiopharmaceuticals, consideration of radiation toxicity is also included, though for 99mTc, chemical toxicity of the ligand is often the primary concern at diagnostic doses.

Preclinical data for JNJ-89853413, for instance, involved cytotoxicity assays and in vivo models to demonstrate its anti-tumor activity.[41] Similarly, preclinical trials for QLM2011 in solid tumors were planned.[42] Studies on HC016 (preconditioned stem cells) investigated mechanisms of oxidative stress resistance and the paracrine effects of its conditioned medium, providing mechanistic and efficacy insights before potential clinical application.[43] These examples illustrate the breadth and depth of non-clinical investigations required to support the transition of a novel agent to human trials.

4.2. Clinical Studies

Clinical trials in humans are conducted in distinct phases to systematically evaluate the safety and efficacy of an investigational drug. ForTc-G3-(G3S)3C, this would involve:

4.2.1. Study Design and Endpoints

• Phase I Trials: Typically the first studies in humans, primarily focused on safety, tolerability, and pharmacokinetics/biokinetics. For a diagnostic radiopharmaceutical likeTc-G3-(G3S)3C, Phase I trials would involve a small number of healthy volunteers or patients. Key objectives would include:
• Assessing safety and tolerability across a range of administered activities.
• Determining human biokinetics through serial blood/urine/fecal sampling and whole-body/SPECT imaging.
• Calculating human radiation dosimetry estimates.
• Identifying the optimal imaging time window.
• Initial assessment of diagnostic performance or target engagement.
• Endpoints: Incidence of adverse events, pharmacokinetic parameters, radiation absorbed doses, image quality, and preliminary evidence of target localization. The TITAN study for AZD5492, a Phase 1 open-label study, has primary endpoints of safety and tolerability [36], which is characteristic of early-phase trials. Similarly, trials for QLM2011 are Phase 1, open-label, dose-escalation studies focusing on safety, tolerability, MTD, and RP2D.[5]
• Phase II Trials: If Phase I results are favorable, Phase II trials are conducted in a larger group of patients with the target disease. For a diagnostic agent, these studies aim to:
• Further evaluate diagnostic performance (e.g., sensitivity, specificity, accuracy) compared to a standard diagnostic modality or histopathology.
• Optimize the imaging protocol and dose.
• Gather more extensive safety data.
• Endpoints: Diagnostic accuracy metrics, image quality scores, correlation with clinical outcomes or other biomarkers, and adverse event rates. The ALPHA3 trial for cema-cel is a pivotal Phase 2 randomized trial with a primary endpoint of event-free survival, demonstrating a later-stage efficacy focus.[46]
• Phase III Trials: Large-scale, often multicenter, randomized controlled trials designed to definitively establish efficacy and safety in the intended patient population and compare the new agent to standard of care, if one exists. For a diagnostic radiopharmaceutical, Phase III trials would:
• Confirm diagnostic performance in a broad patient population.
• Assess the impact of the diagnostic information on patient management and clinical outcomes.
• Provide robust safety data.
• Endpoints: Co-primary endpoints often include sensitivity and specificity, positive and negative predictive values, impact on therapeutic decision-making, and safety.

Understanding the design (e.g., open-label, randomized, placebo-controlled, single-group assignment, crossover), number of participants, specific patient population characteristics, and precisely defined primary and secondary endpoints is fundamental for critically appraising the evidence generated by each trial.

4.2.2. Efficacy Results

This section would present the quantitative results for the primary and secondary efficacy endpoints from each significant clinical trial.

• For a Diagnostic Agent (Tc-G3-(G3S)3C):
• Sensitivity: The proportion of patients with the disease correctly identified by the agent.
• Specificity: The proportion of patients without the disease correctly identified as negative.
• Accuracy: The overall proportion of patients correctly classified.
• Positive Predictive Value (PPV): The probability that a patient with a positive test truly has the disease.
• Negative Predictive Value (NPV): The probability that a patient with a negative test truly does not have the disease.
• Inter- and intra-reader variability for image interpretation.
• Correlation of imaging findings with histopathology or long-term clinical outcomes.
• Impact on diagnostic thinking, therapeutic decision-making, or patient prognosis.
• For a Therapeutic Agent (if applicable):
• Objective response rates (ORR), complete response (CR) rates.
• Duration of response (DOR).
• Progression-free survival (PFS).
• Overall survival (OS).
• Changes in disease-specific biomarkers or patient-reported outcomes.

Efficacy results from trials of other agents illustrate these concepts. For ALLO-501/cema-cel, Phase 1 data showed a 58% complete remission rate in relapsed/refractory LBCL, with more detailed ORR, CR, DOR, and PFS data reported from the combined ALPHA/ALPHA2 trials.[46] Opicapone demonstrated a significant reduction in "OFF-time" and an increase in "ON-time" without troublesome dyskinesia in Parkinson's patients in the BIPARK trials.[33] Zipalertinib showed an ORR of around 38.4% to 41% in pretreated NSCLC patients with EGFR exon 20 insertion mutations.[25] The statistical significance (p-values, confidence intervals) and clinical relevance of these efficacy outcomes are paramount for determining the drug's value.

4.2.3. Safety and Tolerability Data

A comprehensive summary of all safety findings from clinical trials is essential. This includes:

• Adverse Events (AEs): All types of AEs reported, their frequency, severity (graded, e.g., using CTCAE), and relationship to the study drug.
• Serious Adverse Events (SAEs): Detailed description of any SAEs.
• Discontinuations due to AEs: The rate and reasons for patients discontinuing treatment due to adverse effects.
• Specific Safety Concerns: For radiopharmaceuticals, this includes any AEs potentially related to radiation exposure (though typically low for 99mTc diagnostics) or to the ligand itself (e.g., hypersensitivity reactions, physiological effects).
• Laboratory Abnormalities: Clinically significant changes in laboratory parameters (e.g., hematology, liver function, renal function).

Safety findings for AMG-811 in DLE and SLE trials detailed common AEs like arthralgia and headache, as well as SAEs including infections and migraine.[54] For the allogeneic CAR T-cell therapy cema-cel, key safety data include rates of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), graft-versus-host disease (GvHD), infections, and cytopenias.[49] Esaxerenone development highlighted hyperkalemia as a key safety monitoring point.[57] A thorough assessment of the safety profile is critical for the benefit-risk evaluation ofTc-G3-(G3S)3C.

4.2.4. Clinical Trial Registries and Identifiers

To ensure transparency and allow for independent verification of trial information, all significant clinical trials should be referenced with their unique identifiers from public trial registries. Commonly used registries include ClinicalTrials.gov (NCT numbers) and the EU Clinical Trials Register (EudraCT numbers). The provided research materials are rich with such examples:

• QLM2011 trials: NCT06925659, CTR20251241.[5]
• AZD5492 trials: D9961C00001 (TITAN, associated with NCT06916806), NCT06542250 (TITANium).[36]
• ALLO-501 trial (ALPHA): NCT03939026.[62]
• Cema-cel trial (ALPHA3): NCT06500273.[47]
• Zipalertinib trials (REZILIENT series): NCT05967689 (REZILIENT2), NCT04036682 (REZILIENT1), NCT05973773 (REZILIENT3).[17] Providing these identifiers allows readers to access detailed study protocols, inclusion/exclusion criteria, site information, and often, summary results directly from the source registries.

Table 3: Illustrative Overview of Major Non-Clinical Studies for a Novel Radiopharmaceutical (e.g.,Tc-G3-(G3S)3C)

Study Type/Model	Key Objectives	Compound Tested	Dosing (Example)	Key Findings (Efficacy/Targeting)	Key Findings (Safety/Toxicology)
In Vitro Target Binding	Assess affinity & specificity for Target X	G3-(G3S)3C /Tc-G3-(G3S)3C	Concentration range	e.g., Kd​ = Y nM for Target X; >100-fold selectivity over related Target Z	N/A
In Vitro Cell Uptake	Evaluate uptake in Target X-expressing cells vs. control cells	Tc-G3-(G3S)3C	Activity concentration	e.g., Significant uptake in Target X+ cells, blocked by excess unlabeled ligand	N/A
Animal Biodistribution (e.g., Rodent Tumor Model)	Determine in vivo distribution, tumor uptake, clearance, initial dosimetry	Tc-G3-(G3S)3C	e.g., 10 MBq IV	e.g., Peak tumor uptake of Z %ID/g at W hours post-injection; rapid blood clearance; primary renal excretion	e.g., No acute toxicity observed at imaging doses
Safety Pharmacology (e.g., Rat/Dog)	Assess effects on cardiovascular, respiratory, CNS functions	G3-(G3S)3C (unlabeled)	Dose range up to X mg/kg	e.g., No significant effects on HR, BP, RR, or behavior at doses up to Y mg/kg	e.g., No adverse findings at relevant safety multiples of the anticipated human ligand dose
Acute Toxicology (e.g., Rodent)	Determine Maximum Tolerated Dose (MTD) or No Observed Adverse Effect Level (NOAEL)	G3-(G3S)3C (unlabeled)	Single escalating doses	N/A	e.g., NOAEL established at Z mg/kg for the ligand

This table provides a template. Actual studies and findings forTc-G3-(G3S)3C would be specific to its development program.

Table 4: Illustrative Summary of Clinical Trials for a Novel Radiopharmaceutical (e.g.,Tc-G3-(G3S)3C)

Trial ID (e.g., NCT)	Phase	Study Design	No. of Patients	Target Population	Intervention(s)	Primary Endpoint(s)	Key Efficacy Outcome(s) (Illustrative)	Key Safety Outcome(s) (Illustrative)
e.g., NCTxxxxxxx1	Phase I	Open-label, dose-escalation (activity)	e.g., 10-20	Healthy volunteers and/or patients with Target X disease	Tc-G3-(G3S)3C (escalating activities)	Safety, tolerability, PK/biokinetics, radiation dosimetry	e.g., Favorable biokinetics with good target uptake; radiation doses within acceptable limits	e.g., Well-tolerated; no SAEs; common AEs: mild injection site reaction, transient flushing
e.g., NCTxxxxxxx2	Phase II	Single-arm, open-label, diagnostic performance	e.g., 50-100	Patients with suspected Target X disease	Tc-G3-(G3S)3C (optimal activity from PhI)	Sensitivity and specificity for detecting Target X disease (vs. gold standard)	e.g., Sensitivity: 90% (95% CI: X-Y); Specificity: 85% (95% CI: A-B); good inter-reader agreement (kappa = Z)	e.g., Consistent with Phase I safety profile; no new safety signals identified
e.g., NCTxxxxxxx3	Phase III	Randomized, controlled (vs. standard imaging)	e.g., 200-500	Patients eligible for Target X disease diagnosis	Tc-G3-(G3S)3C vs. Standard Imaging Agent	Co-primary: Superiority/Non-inferiority in sensitivity/specificity; Impact on patient management	e.g., Met non-inferiority for sensitivity/specificity; led to change in management in W% more patients compared to standard imaging	e.g., Overall AE rate comparable to standard imaging; specific AE profile consistent with prior studies

This table provides a template. Actual trial details forTc-G3-(G3S)3C would depend on its specific clinical development pathway.

5. Clinical Use and Safety

This section consolidates information pertinent to the practical clinical application ofTc-G3-(G3S)3C, including its intended uses, administration guidelines, and a comprehensive overview of its safety profile.

5.1. Therapeutic or Diagnostic Indications (Approved or Investigational)

A precise statement of the medical condition(s) for whichTc-G3-(G3S)3C is approved by regulatory authorities or is currently under investigation would be provided here. This includes defining the specific patient population (e.g., adults, pediatric patients, specific disease stages or subtypes). For example, Pazufloxacin is indicated for various bacterial infections, including chronic purulent otitis media.[70] Opicapone (Ongentys) is approved as an adjunctive treatment for Parkinson's disease patients experiencing "off" episodes.[33] Tesamorelin (Egrifta) is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.[15] The indication forTc-G3-(G3S)3C would be determined by its validated diagnostic capabilities or therapeutic effects established in clinical trials, such as "for the imaging of X-receptor positive tumors" or "for the assessment of Y physiological process." Clearly defined indications are fundamental for ensuring appropriate and effective clinical use and for regulatory compliance.

5.2. Dosage and Administration

5.2.1. Recommended Dosing Regimen

For a radiopharmaceutical likeTc-G3-(G3S)3C, the recommended dose is typically expressed in units of radioactivity, such as Megabecquerels (MBq) or millicuries (mCi). This section would specify the exact administered activity, the route of administration (usually intravenous for systemic agents), and the frequency (typically a single administration for diagnostic procedures). For example, Opicapone is dosed at 50 mg orally once daily at bedtime [33], while Egrifta WR is 1.28 mg subcutaneously once daily.[21] Tenecteplase dosing is weight-based and administered as a single IV bolus.[23] The optimal radioactivity dose forTc-G3-(G3S)3C would be established during clinical development, balancing image quality (for diagnostics) or therapeutic effect with radiation safety considerations (ALARA principle).

5.2.2. Preparation and Handling

Radiopharmaceuticals require meticulous preparation and handling procedures to ensure product integrity and radiation safety. This subsection would detail:

• Reconstitution and Radiolabeling: IfTc-G3-(G3S)3C is supplied as a kit, step-by-step instructions for reconstituting the ligand vial (e.g., with sterile saline) and for radiolabeling with 99mTcO4−​ obtained from a generator. This includes specifics on volumes, incubation times, and temperatures.
• Quality Control (QC): Post-labeling QC tests to verify radiochemical purity (e.g., using thin-layer chromatography or HPLC) and ensure it meets predefined specifications before patient administration.
• Administration Technique: Specifics of intravenous injection.
• Radiation Safety: Essential radiation safety precautions for personnel involved in handling, preparing, and administering the radiopharmaceutical, as well as for managing the patient post-administration (e.g., advice on hydration, voiding, and proximity to others if radiation levels warrant).

The detailed reconstitution instructions for Egrifta WR [21] and Tenecteplase (TNKase), including its incompatibility with dextrose [23], exemplify the level of detail required for pharmaceutical preparation. ForTc-G3-(G3S)3C, these instructions are compounded by the need for aseptic technique during radiolabeling and adherence to radiation protection guidelines.

5.2.3. Imaging Protocols (if applicable)

IfTc-G3-(G3S)3C is a diagnostic imaging agent, this section is critical. It would outline the recommended imaging procedures to ensure optimal image quality and diagnostic accuracy:

• Patient Preparation: Any necessary patient preparation before administration (e.g., fasting, hydration, premedication).
• Imaging Acquisition Times: Optimal time window(s) post-injection for image acquisition (e.g., early and delayed imaging). This is determined by the agent's pharmacokinetics (target uptake and background clearance).
• Imaging Equipment: Type of gamma camera (e.g., SPECT, SPECT/CT).
• Acquisition Parameters: Specifics such as energy window settings (centered on 140 keV for 99mTc), collimator type, matrix size, zoom factors, acquisition mode (e.g., step-and-shoot, continuous), number of projections, and acquisition time per projection or total scan duration.
• Image Processing and Interpretation: Guidelines for image reconstruction, processing, and criteria for interpretation.

Standardized imaging protocols are vital for obtaining high-quality, reproducible diagnostic information and for allowing comparisons across different clinical sites and studies. While no direct examples for a novel agent likeTc-G3-(G3S)3C are in the provided snippets, this section is a standard and indispensable part of any diagnostic radiopharmaceutical monograph.

5.3. Contraindications

Contraindications are specific clinical situations or patient conditions where the use ofTc-G3-(G3S)3C is absolutely not advised because the potential risks significantly outweigh any potential benefits. For radiopharmaceuticals, common contraindications include:

• Pregnancy: Due to the potential radiation risk to the fetus, most radiopharmaceutical administrations are contraindicated in pregnant patients unless the benefit is life-saving and clearly outweighs the risk. Confirmation of non-pregnant status is often required for female patients of childbearing potential.
• Known Hypersensitivity: Documented severe hypersensitivity reaction toTc-G3-(G3S)3C, the G3-(G3S)3C ligand, or any of its excipients.

Tesamorelin (Egrifta WR), for example, is contraindicated in patients with active malignancy, pregnancy, or known hypersensitivity.[21] Opicapone (Ongentys) is contraindicated with concomitant use of non-selective MAO inhibitors and in patients with certain catecholamine-secreting tumors.[33] Any specific contraindications forTc-G3-(G3S)3C identified during its development would be listed here.

5.4. Warnings and Precautions

This section provides important safety information beyond absolute contraindications, highlighting potential risks, necessary patient monitoring, and specific populations that may require particular caution whenTc-G3-(G3S)3C is administered.

• Radiation Exposure: A general statement regarding radiation exposure, emphasizing that all radiopharmaceutical procedures result in some radiation dose to the patient. The principle of ALARA (As Low As Reasonably Achievable) should be followed, using the minimum radioactivity necessary to achieve the diagnostic or therapeutic objective.
• Hypersensitivity Reactions: Potential for allergic or anaphylactoid reactions. Availability of appropriate medical support should be ensured.
• Renal Impairment: If the agent is primarily cleared by the kidneys, its use in patients with severe renal impairment might require dose adjustment or careful monitoring due to altered pharmacokinetics and potentially increased radiation dose to the kidneys or bladder.
• Hepatic Impairment: Similarly, if hepatobiliary excretion is significant, use in patients with severe hepatic impairment may need consideration.
• Breastfeeding: Recommendations regarding interruption or cessation of breastfeeding after administration to minimize radiation exposure to the infant.
• Pediatric Use: Safety and efficacy in pediatric patients would be specified if studied.
• Geriatric Use: Any specific considerations for elderly patients.

Warnings for Tesamorelin include risks of neoplasms, elevated IGF-1, fluid retention, glucose intolerance, and hypersensitivity reactions.[21] Opicapone carries warnings related to cardiovascular effects with COMT-metabolized drugs, somnolence, hypotension, dyskinesia, and impulse control disorders.[33] Tenecteplase warnings focus on bleeding risks, hypersensitivity, and thromboembolism.[74] ForTc-G3-(G3S)3C, this section would detail any specific warnings identified during its development related to the ligand or the radiopharmaceutical nature of the product.

5.5. Adverse Reactions and Safety Profile

A comprehensive listing and discussion of all adverse drug reactions (ADRs) observed during clinical trials and, if applicable, post-marketing surveillance forTc-G3-(G3S)3C would be presented. ADRs are typically categorized by:

• System Organ Class (SOC): Grouping ADRs by the physiological system affected (e.g., Gastrointestinal disorders, Nervous system disorders).
• Frequency: Using standard frequency categories (e.g., Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000), Very rare (<1/10,000)).
• Severity: Description of the typical severity of reactions.

Common ADRs for Opicapone include dyskinesia, constipation, and increased blood creatine kinase.[33] For Tesamorelin, common ADRs are arthralgia, injection site reactions, peripheral edema, and myalgia.[21] Pazufloxacin Mesilate is associated with adverse events such as erythema and injection site irritation.[71] ForTc-G3-(G3S)3C, ADRs could include injection site reactions, flushing, nausea, dizziness, or allergic-type reactions. The overall safety profile, including the nature, incidence, and management of ADRs, is a critical component of the drug's evaluation.

5.6. Drug Interactions

This subsection details clinically significant interactions betweenTc-G3-(G3S)3C and other medications. These interactions could:

• Affect the pharmacokinetics ofTc-G3-(G3S)3C (e.g., alter its biodistribution, metabolism, or excretion).
• Affect the pharmacodynamics ofTc-G3-(G3S)3C (e.g., interfere with target binding).
• Be affected byTc-G3-(G3S)3C (less common for diagnostic radiopharmaceuticals, but possible if the ligand has pharmacological activity).
• Lead to an increased risk of adverse reactions when co-administered.

Examples include Tesamorelin's interactions with CYP450-metabolized drugs and glucocorticoids.[21] Opicapone interacts with non-selective MAO inhibitors and drugs metabolized by COMT.[35] Esaxerenone shows interactions with CYP3A modulators.[79] Tenecteplase has numerous clinically significant interactions, particularly with anticoagulants and antiplatelet agents, which increase bleeding risk.[23] ForTc-G3-(G3S)3C, particular attention would be paid to drugs that might alter its target expression, receptor binding, or physiological processes that influence its uptake and clearance, as these could impact diagnostic accuracy or therapeutic efficacy.

Table 5: Illustrative Profile of Adverse Reactions Associated with a Novel 99mTc-Radiopharmaceutical (e.g.,Tc-G3-(G3S)3C)

System Organ Class	Adverse Reaction	Frequency Category	Severity (Typical)
General disorders and administration site conditions	Injection site reaction (pain, erythema, swelling)	e.g., Common (≥1/100 to <1/10)	e.g., Mild
	Flushing	e.g., Uncommon (≥1/1,000 to <1/100)	e.g., Mild, transient
	Fatigue	e.g., Uncommon	e.g., Mild
Nervous system disorders	Headache	e.g., Common	e.g., Mild
	Dizziness	e.g., Uncommon	e.g., Mild
Gastrointestinal disorders	Nausea	e.g., Common	e.g., Mild
	Vomiting	e.g., Uncommon	e.g., Mild
Immune system disorders	Hypersensitivity reaction (e.g., rash, pruritus)	e.g., Rare (≥1/10,000 to <1/1,000)	e.g., Mild to Moderate
	Anaphylactoid reaction	e.g., Very rare (<1/10,000)	e.g., Severe

This table is illustrative. Actual ADRs and frequencies forTc-G3-(G3S)3C would be determined from clinical trial data.

Table 6: Illustrative Recommended Dosing and Administration Guidelines for a Novel 99mTc-Radiopharmaceutical (e.g.,Tc-G3-(G3S)3C)

Parameter	Guideline
Patient Population	e.g., Adults aged 18 years and older
Indication	e.g., Diagnostic imaging for the assessment of Target X expression in known or suspected Disease Y
Recommended Dose (Activity)	e.g., 555 - 740 MBq (15 - 20 mCi)
Route of Administration	Intravenous injection (slow bolus over X seconds/minutes)
Preparation Notes	e.g., Reconstitute G3-(G3S)3C kit with Y mL sterile saline. Add Z MBq (W mCi) of 99mTcO4−​ in V mL. Incubate for Q minutes at room temperature. Perform QC for RCP (≥95%).
Administration Notes	e.g., Administer within R hours of preparation. Ensure patient is adequately hydrated.
Imaging Protocol (if diagnostic)
Equipment	e.g., SPECT or SPECT/CT gamma camera
Timing	e.g., Whole-body planar and SPECT/CT of region of interest at S-T hours post-injection.
Key Acquisition Parameters	e.g., Energy window: 140 keV ±10%; Collimator: LEHR/LEAP; Matrix: 128x128; SPECT: X projections, Y sec/projection.
Radiation Safety	Standard precautions for handling 99mTc. Patient to void frequently post-injection to reduce bladder dose.

This table is illustrative. Specific guidelines forTc-G3-(G3S)3C would be based on data from its development program.

6. Regulatory and Manufacturing Landscape

The regulatory approval and consistent manufacturing of a radiopharmaceutical are critical for its availability and safe use in patients. This section would detail the regulatory journey ofTc-G3-(G3S)3C and key aspects of its production.

6.1. Regulatory Status and Approvals

This subsection would provide a comprehensive overview of the regulatory status ofTc-G3-(G3S)3C in major global regions.

• Marketing Authorizations: Information on approvals granted by regulatory agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and China's National Medical Products Administration (NMPA). The dates of approval and specific approved indications would be noted.
• Regulatory Submissions: History of key regulatory submissions (e.g., Investigational New Drug (IND) application, New Drug Application (NDA), Biologics License Application (BLA), Marketing Authorization Application (MAA)).
• Special Designations: Any expedited review pathways or special status designations granted by regulatory authorities, such as Orphan Drug Designation (for rare diseases), Fast Track, Breakthrough Therapy, or Priority Review (FDA terms), or PRIME (PRIority MEdicines) scheme (EMA term). These designations aim to facilitate and expedite the development and review of drugs that address unmet medical needs.

For example, Tesamorelin (Egrifta WR) has received FDA approval, and details of its supplemental Biologics License Application (sBLA) are available.[22] Opicapone (Ongentys) has approvals from both the FDA and EMA.[14] Zipalertinib received Breakthrough Therapy Designation from the FDA [7], and cemacabtagene ansegedleucel (cema-cel) was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA.[87] The regulatory journey ofTc-G3-(G3S)3C, including any such approvals or designations, would be critical to report. The contrasting regulatory outcomes for Tesamorelin, approved in the US but with its EU application withdrawn due to concerns about long-term safety data and trial design [88], underscore the differing perspectives and requirements of global regulatory bodies.

6.2. Manufacturing and Quality Control Highlights

Ensuring the consistent quality, safety, and efficacy of pharmaceutical products, especially complex biologics or radiopharmaceuticals, relies on robust manufacturing processes and stringent quality control (QC) measures.

• Manufacturing Process: Key aspects of the manufacturing ofTc-G3-(G3S)3C would be described. This includes:
• Synthesis and purification of the G3-(G3S)3C ligand.
• If supplied as a kit: Formulation of the kit components, lyophilization process, and assembly under aseptic conditions.
• Radiolabeling procedure: The chemical reaction for complexing 99mTc with the G3-(G3S)3C ligand, including chelator chemistry.
• Quality Control Specifications:
• For the non-radioactive kit: Specifications for identity, purity, quantity of ligand, and sterility.
• For the final radiolabeled product (Tc-G3-(G3S)3C): Specifications for appearance, pH, radiochemical purity (RCP), radionuclide identity and purity, sterility, and apyrogenicity (endotoxin levels). RCP is particularly critical to ensure that the radioactivity is associated with the correct molecular form for targeted delivery.
• Good Manufacturing Practices (GMP): Adherence to GMP is mandatory for pharmaceutical manufacturing. The FDA's initiative on Quality Management Maturity (QMM) highlights the importance of advanced quality systems beyond basic CGMP compliance to ensure supply chain resiliency and minimize drug shortages.[89]

Allogene Therapeutics, for example, emphasizes its manufacturing capabilities for cema-cel, including a scalable process at its Cell Forge 1 facility, designed to produce approximately 100 doses from a single run.[48] ForTc-G3-(G3S)3C, robust manufacturing of the G3-(G3S)3C ligand/kit and reliable, reproducible radiolabeling procedures with stringent QC are essential for its clinical utility.

7. Comprehensive Assessment and Future Outlook

This final section provides a summative evaluation ofTc-G3-(G3S)3C, considering its overall benefit-risk profile, its position relative to existing alternatives, the unmet medical needs it may address, and potential future directions for its development and application.

7.1. Summary of Benefits and Risks

A balanced and critical appraisal of the established or potential benefits ofTc-G3-(G3S)3C against its known or potential risks is essential.

• Benefits: If a diagnostic agent, benefits would relate to its accuracy in detecting or characterizing a disease, its ability to guide treatment decisions, or its advantages over existing diagnostic methods (e.g., less invasive, better tolerated, more cost-effective). If a therapeutic agent, benefits would be measured by clinical efficacy (e.g., tumor response, symptom improvement, survival benefit).
• Risks: These include all adverse reactions identified during clinical development, with particular attention to their frequency and severity. For a radiopharmaceutical, this also includes the risks associated with radiation exposure, however small. Any specific warnings, precautions, or contraindications would be reiterated.

For instance, Tesamorelin offers the benefit of visceral adipose tissue (VAT) reduction in HIV-associated lipodystrophy, but carries risks such as potential glucose intolerance and elevations in IGF-1 levels.[15] Opicapone reduces "off" time in Parkinson's disease but can cause or exacerbate dyskinesia.[33] The benefit-risk assessment forTc-G3-(G3S)3C would be specific to its performance in clinical trials and its intended use.

7.2. Comparison with Existing Agents (if applicable)

If other diagnostic or therapeutic agents are available for the same indication(s) targeted byTc-G3-(G3S)3C, a comparative discussion would be presented. This comparison would ideally be based on head-to-head clinical trial data, but in its absence, could draw upon cross-trial comparisons (while acknowledging their limitations) or differences in mechanism of action, safety profiles, or administration convenience.

• Efficacy Comparison: Relative sensitivity/specificity for diagnostics; relative response rates/survival benefits for therapeutics.
• Safety Comparison: Differences in the type, frequency, or severity of adverse events.
• Other Factors: Differences in dosing regimen, route of administration, cost-effectiveness, or patient convenience.

Numerous clinical trials have compared Tenecteplase to Alteplase for acute ischemic stroke, evaluating non-inferiority or superiority in terms of neurological outcomes and safety (e.g., ATTEST, TRACE-2, NOR-TEST, TIMELESS, ORIGINAL trials).[97] Opicapone has been compared to entacapone in the management of motor fluctuations in Parkinson's disease.[50] Such comparative assessments help to positionTc-G3-(G3S)3C within the existing therapeutic or diagnostic armamentarium.

7.3. Unmet Medical Needs Addressed

This section would discuss howTc-G3-(G3S)3C potentially fulfills unmet medical needs in the diagnosis or treatment of its target condition(s). This could involve:

• Providing a diagnostic tool for a condition with no current effective imaging modality.
• Offering improved diagnostic accuracy, leading to better patient stratification or earlier intervention.
• Providing a novel therapeutic mechanism for a disease resistant to current treatments.
• Offering a safer or better-tolerated alternative to existing therapies.
• Improving patient convenience or quality of life.

Zipalertinib, for example, aims to address the unmet need for effective treatments in NSCLC with EGFR exon 20 insertion mutations, a population often resistant to other EGFR TKIs.[24] Tesamorelin addresses HIV-associated lipodystrophy, a condition with limited specific treatment options that can significantly impact patient well-being.[15] Highlighting the specific unmet needs thatTc-G3-(G3S)3C could address underscores its potential clinical impact and relevance.

7.4. Potential Future Research and Development Directions

The development of a pharmaceutical agent is often an ongoing process. This subsection would outline potential future avenues for research and development involvingTc-G3-(G3S)3C:

• Ongoing or Planned Clinical Trials: Further studies to confirm efficacy, explore new indications, or evaluate use in different patient populations (e.g., pediatrics, specific comorbidities).
• Combination Strategies: IfTc-G3-(G3S)3C is a diagnostic, research into how it can be combined with specific therapies to guide treatment. If therapeutic, potential combinations with other anticancer agents or supportive care.
• Development of Analogs or Related Compounds: If G3-(G3S)3C proves to be a valuable targeting vector, future research might involve labeling it with other radionuclides for different applications (e.g., PET imaging radionuclides like 68Ga or 18F for potentially higher resolution or quantification; therapeutic radionuclides like Lutetium-177 (177Lu) or Actinium-225 (225Ac) if the targeting is highly specific and suitable for radioligand therapy).
• Biomarker Development: Research into biomarkers that could predict response toTc-G3-(G3S)3C (if therapeutic) or that correlate with its diagnostic findings.

Allogene Therapeutics' ALPHA3 trial for cema-cel, aiming to establish its role as a first-line consolidation therapy in Large B-Cell Lymphoma, exemplifies a strategic future development direction.[46] The exploration of Tesamorelin for non-HIV related non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) indicates potential indication expansion.[110] This forward-looking perspective outlines the continued evolution and potential broadening of the clinical utility ofTc-G3-(G3S)3C.

8. Conclusions

This report has outlined the comprehensive framework necessary for the evaluation of a novel radiopharmaceutical candidate such asTc-G3-(G3S)3C. While specific data pertaining directly to this agent were not available within the provided reference materials, the structure presented reflects the rigorous scientific and clinical assessment required for any new drug, with particular emphasis on the unique aspects of radiopharmaceuticals.

A complete monograph would begin with unambiguous nomenclature and a clear overview of the agent's intended purpose. The scientific profile must meticulously detail its physicochemical properties, the characteristics of the 99mTc radionuclide, formulation specifics, and the elucidated mechanism of action, which is fundamentally tied to the biological targeting properties of the G3-(G3S)3C ligand.

The pharmacological profile, encompassing pharmacodynamics and pharmacokinetics (biokinetics), is crucial. For a 99mTc-based agent, biokinetic data directly informs the critical radiation dosimetry calculations, which are paramount for patient safety and risk-benefit assessment. Evidence of target engagement and the biological consequences of such interaction would be detailed under pharmacodynamics.

The development program section would summarize the journey from non-clinical in vitro and in vivo studies (establishing proof-of-concept, initial safety, and biodistribution) through phased clinical trials (evaluating safety, biokinetics, dosimetry, and diagnostic/therapeutic efficacy in humans). The design, endpoints, and outcomes of these studies form the core evidence base.

Clinical use and safety considerations would consolidate information on approved or investigational indications, precise dosage and administration protocols (including radiolabeling and imaging procedures if applicable), contraindications, warnings, a full adverse reaction profile, and potential drug interactions.

Finally, the regulatory and manufacturing landscape, including approvals from major health authorities and highlights of GMP-compliant manufacturing and quality control, would be described. A comprehensive assessment would synthesize the benefits and risks, compare the agent to existing alternatives, identify the unmet medical needs it addresses, and explore future research directions.

The successful development and introduction of any new radiopharmaceutical rely on a robust body of evidence covering all these domains. ForTc-G3-(G3S)3C, future research and publication of specific data will be necessary to populate this framework and fully delineate its potential role in clinical medicine. The illustrative examples drawn from other pharmaceutical agents throughout this report highlight the depth and breadth of information that would be expected.

Works cited

1. Pl-3994 | C82H127N27O20S2 | CID 121488161 - PubChem, accessed May 12, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Pl-3994
2. PL-3994 | natriuretic cyclic peptide | CAS#952295-80-6 | MedKoo, accessed May 12, 2025, https://www.medkoo.com/products/56254
3. CAS 1632006-28-0 Esaxerenone - BOC Sciences, accessed May 12, 2025, https://www.bocsci.com/esaxerenone-cas-1632006-28-0-item-74260.html
4. Esaxerenone | CAS#1632006-28-0 | aldosterone receptor antagonist | MedKoo, accessed May 12, 2025, https://www.medkoo.com/products/7449
5. QLM2011 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 12, 2025, https://synapse.patsnap.com/drug/158d05ab0de5464a8dfb265e28500452
6. FAB 117-HC - AdisInsight, accessed May 12, 2025, https://adisinsight.springer.com/drugs/800045592
7. Zipalertinib - Cullinan Therapeutics - AdisInsight - Springer, accessed May 12, 2025, https://adisinsight.springer.com/drugs/800056381
8. CLN-081: A Promising Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations - ClinicalTrials.eu, accessed May 12, 2025, https://clinicaltrials.eu/inn/cln-081/
9. Tenecteplase: a review - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/11519775/
10. Tenecteplase: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed May 12, 2025, https://go.drugbank.com/drugs/DB00031
11. Pazufloxacin VETRANAL , analytical standard 127045-41-4, accessed May 12, 2025, https://www.sigmaaldrich.com/GB/en/product/sial/34213?context=
12. pazufloxacin | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed May 12, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12410
13. What is the mechanism of Opicapone? - Patsnap Synapse, accessed May 12, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-opicapone
14. Opicapone - BIAL - AdisInsight - Springer, accessed May 12, 2025, https://adisinsight.springer.com/drugs/800031698
15. Executive Summary - Clinical Review Report: Tesamorelin (Egrifta) - NCBI Bookshelf, accessed May 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK539124/
16. Tesamorelin-A New Hope For Lipodystrophy In HIV Patients - JK Science, accessed May 12, 2025, https://www.jkscience.org/archive/volume132/Tesamorelin-A%20New%20Hope%20For%20Lipodystrophy%20In%20HIV%20Patients.pdf
17. REZILIENT2 - NHS Health Research Authority, accessed May 12, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/rezilient2/
18. Zipalertinib: A Promising Treatment for Advanced Non-Small Cell Lung Cancer with EGFR Mutations - Clinical trials, accessed May 12, 2025, https://clinicaltrials.eu/inn/zipalertinib/
19. Pazufloxacin | 127045-41-4 - ChemicalBook, accessed May 12, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2423188.htm
20. Tenecteplase (TNK-tPA) | Plasminogen Activator - MedchemExpress.com, accessed May 12, 2025, https://www.medchemexpress.com/tenecteplase.html
21. www.accessdata.fda.gov, accessed May 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
22. Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy, accessed May 12, 2025, https://www.theratech.com/news-releases/news-release-details/theratechnologies-receives-fda-approval-egrifta-wrtm-tesamorelin/
23. www.accessdata.fda.gov, accessed May 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/103909s5197lbl.pdf
24. Full article: REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC - Taylor & Francis Online, accessed May 12, 2025, https://www.tandfonline.com/doi/full/10.1080/14796694.2025.2457294
25. Zipalertinib in EGFR Exon 20–Mutant Non–Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting - ASCO Publications, accessed May 12, 2025, https://ascopubs.org/doi/10.1200/JCO.23.00958
26. New emerging targets in cancer immunotherapy: the role of VISTA ..., accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7305420/
27. VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses - PMC, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8528208/
28. DNA Gyrase and Topoisomerase IV Are Dual Targets of Clinafloxacin Action in Streptococcus pneumoniae - PMC, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC105948/
29. Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance - PMC, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5008060/
30. Tesamorelin administration study: urinary detection window and influence on serum IGF-1 and P-III-NP concentrations - WADA, accessed May 12, 2025, https://www.wada-ama.org/en/resources/scientific-research/tesamorelin-administration-study-urinary-detection-window-and
31. Tesamorelin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed May 12, 2025, https://go.drugbank.com/drugs/DB08869
32. What is the mechanism of Tesamorelin Acetate? - Patsnap Synapse, accessed May 12, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-tesamorelin-acetate
33. www.accessdata.fda.gov, accessed May 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212489s000lbl.pdf
34. Opicapone Pharmacokinetics and Effects on Catechol-O ..., accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10010692/
35. Impact of COMT Enzyme - ONGENTYS® (opicapone) capsules, accessed May 12, 2025, https://www.ongentyshcp.com/impact-of-comt/
36. A Study to Investigate Safety, Tolerability, Pharmacokinetics, and ..., accessed May 12, 2025, https://www.astrazenecaclinicaltrials.com/study/D9961C00001/
37. Penetration of Pazufloxacin into the Fluid of Suction Blisters Induced in Human Skin, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/29681382/
38. Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone ..., accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/30541878/
39. Tesamorelin - Wikipedia, accessed May 12, 2025, https://en.wikipedia.org/wiki/Tesamorelin
40. Possible involvement of P-glycoprotein in renal excretion of pazufloxacin in rats - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/15464074/
41. www.jnjmedicalconnect.com, accessed May 12, 2025, https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/discovery-of-jnj89853413-a-firstinclass-cd33xv2-tcell-engager-for-the-treatment-of-acute-myeloid-leu.pdf
42. QLM 2011 - AdisInsight - Springer, accessed May 12, 2025, https://adisinsight.springer.com/drugs/800082087
43. H2O2-preconditioned human adipose-derived stem cells (HC016 ..., accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7397657/
44. Conditioned Medium from H2O2-Preconditioned Human Adipose ..., accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9598226/
45. ADHAirE : a Randomized Controlled Trial to Improve the ..., accessed May 12, 2025, https://app.trialscreen.org/trials/phase-1-qlm2011-subjects-advanced-solid-tumors-trial-nct06925659
46. ALPHA3 - Allogene, accessed May 12, 2025, https://allogene.com/alpha3/
47. A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response to first line therapy for large B-cell lymphoma (ALPHA3) - MD Anderson Cancer Center, accessed May 12, 2025, https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2024-0431.html?PageSpeed=noscript
48. Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma, accessed May 12, 2025, https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-announces-2024-platform-vision-redefine/
49. Allogeneic Chimeric Antigen Receptor T-Cell Products ..., accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12058369/
50. The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9446144/
51. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/28027332/
52. Zipalertinib Meets Primary ORR End Point in EGFR exon 20 NSCLC - Cancer Network, accessed May 12, 2025, https://www.cancernetwork.com/view/zipalertinib-meets-primary-orr-end-point-in-egfr-exon-20-nsclc
53. REZILIENT1 Study of Zipalertinib in Pretreated EGFR-Mutant NSCLC Meets ORR Primary End Point - OncLive, accessed May 12, 2025, https://www.onclive.com/view/rezilient1-study-of-zipalertinib-in-pretreated-egfr-mutant-nsclc-meets-orr-primary-end-point
54. Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of ..., accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5434930/
55. Safety, pharmacokinetics and pharmacodynamics of AMG 811, an ..., accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5604705/
56. ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting ..., accessed May 12, 2025, https://ashpublications.org/blood/article/142/Supplement%201/2095/501915/ALLO-647-for-Lymphodepletion-in-the-Allogeneic-CAR
57. Efficacy and Safety of Esaxerenone in Hypertensive Patients with ..., accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10567833/
58. Safety and efficacy of esaxerenone in Japanese hypertensive ..., accessed May 12, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0259485
59. Management of hyperkalemia during treatment with ..., accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8019656/
60. A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T cell ..., accessed May 12, 2025, https://www.astrazenecaclinicaltrials.com/study/D9960C00001/
61. A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. - National Cancer Institute, accessed May 12, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-07237
62. Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells ..., accessed May 12, 2025, https://clinicaltrials.stanford.edu/trials/s/NCT03939026.html
63. Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma - NCI, accessed May 12, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2019-03206
64. A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2) - ClinicalTrials.Veeva, accessed May 12, 2025, https://ctv.veeva.com/study/a-study-of-zipalertinib-in-patients-with-advanced-non-small-cell-lung-cancer-with-epidermal-growth-f
65. REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations. - ASCO, accessed May 12, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT461768
66. REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) - NCI, accessed May 12, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-08286
67. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT05967689
68. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT05973773
69. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT04036682
70. Pazufloxacin Mesilate - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 12, 2025, https://synapse.patsnap.com/drug/fbefa442504f4762b50cb020592ac49d
71. PAZUFLOXACIN MESILATE - Inxight Drugs - ncats, accessed May 12, 2025, https://drugs.ncats.io/drug/2XI226J1HS
72. What is Pazufloxacin Mesilate used for? - Patsnap Synapse, accessed May 12, 2025, https://synapse.patsnap.com/article/what-is-pazufloxacin-mesilate-used-for
73. Ongentys (opicapone) dosing, indications, interactions, adverse effects, and more, accessed May 12, 2025, https://reference.medscape.com/drug/ongentys-opicapone-4000021
74. TNKase® Acute ST Elevation Myocardial Infarction Treatment, accessed May 12, 2025, https://www.tnkase.com/stemi.html
75. TNK tPA, TNKase (tenecteplase) dosing, indications, interactions ..., accessed May 12, 2025, https://reference.medscape.com/drug/tnk-tpa-tnkase-tenecteplase-342291
76. Tesamorelin (subcutaneous route) - Mayo Clinic, accessed May 12, 2025, https://www.mayoclinic.org/drugs-supplements/tesamorelin-subcutaneous-route/description/drg-20074632
77. Egrifta (Tesamorelin Injection): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed May 12, 2025, https://www.rxlist.com/egrifta-drug.htm
78. Egrifta WR (tesamorelin) dosing, indications, interactions, adverse effects, and more., accessed May 12, 2025, https://reference.medscape.com/drug/egrifta-tesamorelin-999613
79. Hyperkalemic effect of drug–drug interaction between esaxerenone and trimethoprim in patients with hypertension: a pilot study - PMC, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11295366/
80. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8724184/
81. Egrifta WR (tesamorelin) FDA Approval History - Drugs.com, accessed May 12, 2025, https://www.drugs.com/history/egrifta-wr.html
82. FDA Approves F8 Formulation of Theratechnologies' Tesamorelin for HIV-Associated Lipodystrophy - Contagion Live, accessed May 12, 2025, https://www.contagionlive.com/view/fda-approves-f8-formulation-of-theratechnologies-tesamorelin-for-hiv-associated-lipodystrophy
83. FDA approves ONGENTYS® (opicapone) | Business Wire - Via TT, accessed May 12, 2025, https://via.tt.se/pressmeddelande/3276066/fda-approves-ongentys-opicapone?publisherId=259167
84. Ongentys | European Medicines Agency (EMA), accessed May 12, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/ongentys
85. Generic Ongentys Availability - Drugs.com, accessed May 12, 2025, https://www.drugs.com/availability/generic-ongentys.html
86. Zipalertinib - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 12, 2025, https://synapse.patsnap.com/drug/7941d652df79494abfab7ef42f424976
87. Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma, accessed May 12, 2025, https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-and-foresight-diagnostics-announce/
88. Theratechnologies withdraw EU application for tesamorelin (Egrifta) | HTB - HIV i-Base, accessed May 12, 2025, https://i-base.info/htb/19769
89. Lessons from CDER's Quality Management Maturity Pilot Programs - PMC, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9831683/
90. CDER Quality Management Maturity - FDA, accessed May 12, 2025, https://www.fda.gov/drugs/pharmaceutical-quality-resources/cder-quality-management-maturity
91. Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies | Journal of Clinical Oncology - ASCO Publications, accessed May 12, 2025, https://ascopubs.org/doi/10.1200/JCO-24-01933
92. Visceral Fat Reduction with Tesamorelin Is Associated with Improved Liver Enzymes in HIV - PMC, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5633509/
93. Reduction in Visceral Adiposity Is Associated With an Improved Metabolic Profile in HIV-Infected Patients Receiving Tesamorelin - Oxford Academic, accessed May 12, 2025, https://academic.oup.com/cid/article/54/11/1642/322418
94. Clinical Insights on HIV-Associated Visceral Fat Following FDA Approval of Tesamorelin F8, accessed May 12, 2025, https://www.contagionlive.com/view/clinical-insights-on-hiv-associated-visceral-fat-following-fda-approval-of-tesamorelin-f8
95. Tesamorelin - LiverTox - NCBI Bookshelf, accessed May 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548730/
96. Opicapone: A third generation COMT inhibitor - PMC - PubMed Central, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8299985/
97. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/25726502/
98. Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial, accessed May 12, 2025, https://svn.bmj.com/content/early/2024/01/30/svn-2023-002694
99. Tenecteplase vs. Alteplase for Patients With Acute Ischemic Stroke - ORIGINAL, accessed May 12, 2025, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2024/09/25/14/33/original
100. Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/39424558/
101. Thrombolysis in Imaging-Eligible, Late-Window Patients to Assess the Efficacy and Safety of Tenecteplase - TIMELESS, accessed May 12, 2025, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2024/02/20/13/39/timeless
102. Tenecteplase Thrombolysis for Stroke up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial, accessed May 12, 2025, https://www.ahajournals.org/doi/10.1161/STROKEAHA.124.048375
103. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/35525250/
104. Tenecteplase Reperfusion therapy in Acute ischemic Cerebrovascular Events-2 - TRACE-2, accessed May 12, 2025, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/02/21/21/35/trace-2
105. Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke, accessed May 12, 2025, https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.025041
106. Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson's disease,, accessed May 12, 2025, https://pdexpertinstitute.com/mds-2024_ongentys-vs-entacapone-2/
107. Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's new to COMT inhibitor treatment - ResearchGate, accessed May 12, 2025, https://www.researchgate.net/publication/372620921_Opicapone_versus_entacapone_Head-to-head_retrospective_data-based_comparison_of_healthcare_resource_utilization_in_people_with_Parkinson's_new_to_COMT_inhibitor_treatment
108. REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/39957151/
109. Landscape and clinical implications of EGFR exon 20 insertions in non-small cell lung cancer patients - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/40186089/
110. Tesamorelin Promising in People With HIV and NAFLD - Contagion Live, accessed May 12, 2025, https://www.contagionlive.com/view/tesamorelin-promising-in-people-with-hiv-and-nafld
111. Tesamorelin, liver fat, and NAFLD in the setting of HIV - Comment / Tesamorelin Prevented Progression to Liver Fibrosis in NIH Study - NATAP - HIV, accessed May 12, 2025, https://www.natap.org/2019/HIV/102519_02.htm